The company’s success demonstrates the futility of the U.S. policy of subsidies and sanctions.

AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive immunology portfolio.

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

Get the latest car news, reviews, and features.